Many in venture capital and biopharma are anointing artificial intelligence the savior of drug discovery—but what can AI actually do?In this eye-opening episode, Michael Marks sits down with Mike Nohaile, CEO of Prellis Biologics, to explore the hype versus reality in AI-enabled drug discovery. Mike details why, despite significant breakthroughs like AlphaFold and recent Nobel Prize win for computational protein design, fully AI-generated medicines still present challenges. He also discusses why we urgently need more effective medicines and details Prellis’ unique system which combines laser printed human organoids and an externalized human immune system with AI, enabling the discovery of fully human antibodies. If you enjoy this episode, please subscribe and leave us a review on your favorite podcast platform. Sign up for our newsletter at techsurgepodcast.com for exclusive insights and updates on upcoming TechSurge Live Summits.Links:Explore Prellis Biologics<a href="https://prellisbio.com/">https://prellisbio.com/</a>Understand AlphaFold, DeepMind’s AI model for predicting protein structures<a href="https://deepmind.google/alphafold">https://deepmind.google/alphafold</a>Read about the 2024 Nobel Prize in Chemistry <a href="https://www.nobelprize.org/prizes/chemistry/2024/press-release/">https://www.nobelprize.org/prizes/chemistry/2024/press-release/</a>

Podurama

Home

Trending

Personal

Your Podcasts

New Episodes

My Files

Favourite Episodes

Tags (Folders)

Recently Played

Bookmarks

Followed Playlists

Hype vs. Reality: Why AI Isn't Ready to Make Medicines Yet

TechSurge: Deep Tech VC Podcast

AI Chapters

AI Insights

Reviews